Quality by design (QbD)-driven formulation of sildenafil citrate microparticles using quasi-emulsion technique for pulmonary delivery: an in vitro study
Abstract
Abstract Objective The goal of this research was to create inhalable microparticles to ensure the continuous delivery of sildenafil citrate (SC) to treat pulmonary arterial hypertension (PAH). This was done to address the limitations of SC, including its short half-life and systemic side effects. Methods To create the inhalable microparticles, a particle engineering method called the quasi-emulsion solvent diffusion method was utilized. The study employed quality by design (QbD), a regulatory-based approach, to enhance the final product’s quality. The optimization of microparticles was achieved using central composite design to enhance micromeritics properties and sustain drug release profiles. Characterization studies, including FTIR, differential scanning calorimetry (DSC), scanning electron microscopy, XRD, and surface morphology analysis, were conducted to evaluate the microparticles. Aerodynamic properties were measured to predict where particles will be deposited in the respiratory tract. Results The optimized formulated microparticles had an acceptable mean particle size and an entrapment efficiency greater than 90%. The optimized microparticles demonstrated a sustained drug release of 80.42 ± 0.23% over 24 h. Aerodynamic properties showed a mass median aerodynamic diameter of 3.45 ± 0.0 µm, a fine particle fraction of 21%, and 77.29 ± 2.9% of the dose recovered from the inhaler. Modified tapped density measurements indicated improved flow properties of the…
Read the paper
Related studies
- 2024 update in heart failure
- Vascular involvement in idiopathic pulmonary fibrosis
- A novel technique- subendometrial autologous platelet rich plasma injection in patients with unresponsive thin endometrium undergoing frozen-thawed embryo transfer: a prospective cohort study
- Does metformin prolong pregnancy in preterm pre-eclampsia? A study protocol for a South African, hospital-based double-blind, randomised, placebo-controlled trial
- Combined Pulmonary Fibrosis and Emphysema (CPFE): A "New" Smoking-Related Interstitial Lung Disease (ILD)
- Impact of an acute 1-month cannabidiol treatment on pain and inflammation after a long bone fracture: a triple-blind randomised, placebo-controlled, clinical trial protocol
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.